Opthea Ltd
CKDXF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CKDXF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CKDXF
Opthea Ltd is a clinical-stage biopharmaceutical company focused on developing sozinibercept for retinal diseases, currently undergoing a strategic review after its Phase 3 trials failed to meet primary endpoints.
Key risk: Going concern risk
Market Cap
$13.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Tracking 3 clinical trials for Opthea Ltd.
Opthea Ltd is a clinical-stage biopharmaceutical company focused on developing sozinibercept for retinal diseases, currently undergoing a strategic review after its Phase 3 trials failed to meet primary endpoints.
- Opthea's lead product candidate, sozinibercept, targets VEGF receptor 3 for retinal diseases; development began in 2013 [sec · filed 2025-09-15].
- As of June 30, 2025, the company had cash and equivalents of US$48.4 million, but after the DFA Settlement, cash on hand was US$20 million as of August 20, 2025 [sec · filed 2025-09-15].
- The company has never generated revenue from product sales and has an accumulated loss of US$742.5 million as of June 30, 2025 [sec · filed 2025-09-15].
- In March 2025, the COAST and ShORe Phase 3 trials for sozinibercept in wet AMD did not meet primary endpoints, leading to discontinuation of clinical programs and a strategic review [sec · filed 2025-09-15].
- Current cash is expected to fund operations into the fourth calendar quarter of 2026, including completion of the strategic review [sec · filed 2025-09-15].
What works
- Opthea has raised substantial capital, totaling US$377.3 million through June 2025 via ordinary share issuances, indicating prior investor support [sec · filed 2025-09-15].
- The company has a focused intellectual property portfolio around VEGF receptor 3, acquired in 2007, which may be leveraged for reformulation or other indications [sec · filed 2025-09-15].
- The DFA Settlement in August 2025 resolved a major financial obligation, releasing liens and terminating the DFA, which may simplify the capital structure [sec · filed 2025-09-15].
What to weigh
- Opthea has no approved products, no revenue from product sales, and has incurred net losses since inception, with a total comprehensive loss of US$220.2 million in fiscal 2024 [sec · filed 2025-09-15].
- The Phase 3 COAST and ShORe trials failed to meet primary endpoints in March 2025, leading to discontinuation of the lead program and a strategic review [sec · filed 2025-09-15].
- As of August 20, 2025, the company had only US$20 million in cash with no committed external funding, and expects cash to last only into Q4 2026 [sec · filed 2025-09-15].
- The company faces significant uncertainty regarding its ability to continue as a going concern, with risks related to reformulation and future clinical trial costs [sec · filed 2025-09-15].
From the filings
Quoted directly from source documents.
Opthea's lead candidate sozinibercept failed Phase 3 trials in March 2025
“In March 2025, after the primary endpoints were not met in our COAST and ShORe Phase 3 trials, Opthea and the DFA Investors agreed”
SEC filings · September 15, 2025
Accumulated losses of US$742.5 million as of June 30, 2025
“As of June 30, 2025, we had an accumulated loss of US$742.5 million.”
SEC filings · September 15, 2025
Cash on hand of US$20 million after DFA Settlement as of August 20, 2025
“Following the DFA Settlement, as of August 20, 2025 we have $20 million in cash on hand.”
SEC filings · September 15, 2025
No revenue from product sales and net losses since inception
“We have not generated any revenue from product sales to date, and we continue to incur significant research and development and other expenses related to our ongoing operation”
SEC filings · September 15, 2025
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash only expected to fund operations into Q4 2026; no committed external funding [sec · filed 2025-09-15]
- Clinical trial failure — Phase 3 trials for sozinibercept failed primary endpoints, leading to program discontinuation [sec · filed 2025-09-15]
- No approved products or revenue — Company has never generated product revenue and has significant accumulated losses [sec · filed 2025-09-15]
- Reformulation uncertainty — Future depends on successful reformulation and new clinical trials, which are uncertain [sec · filed 2025-09-15]
What to watch
- Outcome of the strategic review process, which is expected to be completed within the current cash runway into Q4 2026 [sec · filed 2025-09-15].
- Ability to secure additional financing or a partnership, given no committed external sources of funds [sec · filed 2025-09-15].
- Progress in reformulating existing therapeutic products and exploring other anti-VEGF indications [sec · filed 2025-09-15].
- Any regulatory or clinical developments for future product candidates emerging from the strategic review [sec · filed 2025-09-15].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Opthea Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Opthea Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 22, 2026- % of float
- 0.4%
- Days to cover
- —
- Shares short
- 537,820
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CKDXF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Opthea Ltd?
Opthea Ltd is a clinical-stage biopharmaceutical company focused on developing sozinibercept for retinal diseases, currently undergoing a strategic review after its Phase 3 trials failed to meet primary endpoints.
Who is the CEO of Opthea Ltd?
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. is the chief executive officer of Opthea Ltd (CKDXF).
Where is Opthea Ltd headquartered?
Opthea Ltd (CKDXF) is headquartered in Melbourne, VIC, Australia.
What therapeutic areas does Opthea Ltd focus on?
Opthea Ltd develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.